Project Grant R44DK134212
Award Date 8/5/22
Completion Date 7/31/23
Dollars Obligated $3.6M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $808,866 to Progenra Inc., a biotechnology firm located in Malvern, Pennsylvania. The funding supports research to evaluate novel small molecule compounds that activate the ubiquitin proteasome system (UPS) as potential therapeutics for treating acute and chronic pancreatitis. Key objectives include assessing...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $324,984 Project Grant to Syntis Bio Inc. located in Massachusetts. The grant funding supports the development of an innovative oral therapy for treating homocystinuria, a rare metabolic disorder. Specifically, Syntis Bio is creating a once-daily oral therapy that combines a gastrointestinal synthetic epithelial...
- This federal Project Grant award of $354,992, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, aims to develop a novel Malabsorption Blood Test (MBT) to identify patients with mild to moderate exocrine pancreatic insufficiency (EPI) among those with recurrent acute pancreatitis (RAP) or chronic pancreatitis (CP). The key objectives are to use the MBT to detect subclinical EPI...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotechnology company based in Blacksburg, Virginia. The grant supports the development of next-generation oral precision medicine therapeutics for the treatment of pre-diabetes and type 2 diabetes. The key objectives are to evaluate the translational...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $147,486 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Chicago. The grant, awarded on September 30, 2025, will fund research to comprehensively establish the role of gut microbes in modulating pancreatic interleukin-22 (IL-22) levels and the consequences of this gut-to-pancreas axis on pancreatic health and disease. The...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a component of the National Institutes of Health, awarded a $324,793 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Nucb1 Holdings LLC. The funding supports the development of a novel platform technology for discovering conformation-specific, anti-protofibril monoclonal antibodies (mAbs) that target intermediate amyloid aggregates implicated in the...
- This federal Project Grant award of $1,021,719 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The funding supports the development and advancement of a novel small molecule compound, EMMY1-25, by the company Emmyon, Inc. for the treatment of obesity and type 2 diabetes. Through this Phase II SBIR award, Emmyon will further investigate the safety, efficacy,...
- This Project Grant award of $306,867, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is for the development of a new drug to treat transplant-associated renal ischemia-reperfusion injury. The goal is to create a therapy that can reduce inflammation and thrombosis without increasing vascular leakage and bleeding, which are common issues with existing treatment...
- Amdx Prognostx Inc. received a $791,145 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases within the Department of Health and Human Services. The award falls under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), which promotes biomedical research to improve understanding and treatment of diabetes, digestive, and kidney diseases. Under this award, Amdx Prognostx will develop an enzyme-linked immunosorbent assay...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $292,116 Project Grant to Renovate Biosciences Inc. on September 25, 2025. The goal of this grant is to generate human livers from donor patient-specific cells using pigs as a "bio-incubator" for xenotransplantation. This research aims to provide a pathway for generating "on-demand"...